Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
Positron Emission Tomography01:29

Positron Emission Tomography

Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body being...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Circulating Tumor Cells Enhance Prognostic Stratification Beyond ER Assessment by Biopsy or FES-PET in Endocrine-Treated Metastatic Breast Cancer.

Diagnostics (Basel, Switzerland)·2026
Same author

18F-Fluorodeoxyglucose Positron Emission Tomography for Estimating Outcomes After Initial Treatment for Metastatic Breast Cancer: A Nonrandomized Clinical Cohort Trial.

JAMA oncology·2026
Same author

Improving patient understanding of oncology imaging: radiologist and patient evaluation of summarised versus full-length AI-simplified reports from a tertiary cancer centre.

Cancer imaging : the official publication of the International Cancer Imaging Society·2026
Same author

[<sup>18</sup>F]F-FAPI PET/CT and LAparoscopy in STagIng advanced gastric Cancer: a multicenter prospective study (PLASTIC-3 study).

BMC cancer·2025
Same author

Four-dimensional Computed Tomography Imaging in Primary Hyperparathyroidism: Multireader Multicase Study of Both Neuroradiologists and General Radiologists of Imaging Approaches With Less Phases.

Journal of computer assisted tomography·2025
Same author

How to foster new treatment development in ultra-rare tumours? Joint EMA-EORTC multi-stakeholder workshops on ultra-rare sarcomas as a model for rare cancers.

Cancer treatment reviews·2025

Related Experiment Video

Updated: Jun 20, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Molecular imaging of solid tumors: exploiting the potential.

Wim J G Oyen1, Winette T A van der Graaf

  • 1Department of Nuclear Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. w.oyen@nucmed.umcn.nl

Nature Reviews. Clinical Oncology
|September 30, 2009
PubMed
Summary
This summary is machine-generated.

Novel targeted cancer therapies require new ways to measure effectiveness beyond tumor size. Molecular imaging shows promise for assessing early treatment response and guiding therapy decisions in oncology.

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Radionuclide-fluorescence Reporter Gene Imaging to Track Tumor Progression in Rodent Tumor Models
10:04

Radionuclide-fluorescence Reporter Gene Imaging to Track Tumor Progression in Rodent Tumor Models

Published on: March 13, 2018

Related Experiment Videos

Last Updated: Jun 20, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Radionuclide-fluorescence Reporter Gene Imaging to Track Tumor Progression in Rodent Tumor Models
10:04

Radionuclide-fluorescence Reporter Gene Imaging to Track Tumor Progression in Rodent Tumor Models

Published on: March 13, 2018

Area of Science:

  • Oncology
  • Molecular Imaging
  • Pharmacodynamics

Background:

  • Targeted cancer therapies often lead to disease stabilization, not shrinkage.
  • Current assessment methods (e.g., tumor size) may not reflect the activity of novel agents.
  • Long-term administration of targeted therapies necessitates new evaluation strategies.

Purpose of the Study:

  • To highlight the need for noninvasive methods to assess molecular features of tumors during targeted therapy.
  • To explore the potential of molecular imaging in predicting early treatment response and resistance.
  • To determine if molecular imaging can inform therapy interruption decisions.

Main Methods:

  • Review of current understanding of targeted therapy effects.
  • Discussion of molecular imaging techniques, specifically Positron Emission Tomography (PET).
  • Analysis of existing (small, retrospective) study data on molecular imaging in oncology.

Main Results:

  • Changes in molecular features, not tumor size, may better indicate targeted therapy activity.
  • Molecular imaging techniques like PET show potential for providing clinically relevant data.
  • Current data is limited, primarily from small, observational studies.

Conclusions:

  • Noninvasive molecular imaging is needed to evaluate early response and resistance to targeted cancer therapies.
  • Further clinical trials are essential to validate molecular imaging's role in oncology practice.
  • Molecular imaging could potentially guide treatment decisions and optimize therapy duration.